Ask Warren

JONBUR Research · Initiation

You're reading an earlier report from Oct 18, 2026. See the latest report

Chong Kun Dang Pharmaceutical · 185750 · Biotech & Pharma

Chong Kun Dang Pharmaceutical: Margins Have Fallen from the 2023 Peak While Shares Trade Near Book Value

Why this report

Start of coverage: written when a reader opened this company and there was no report yet.

Chong Kun Dang's shares closed at ₩66,400 on 2026-10-16, down 18.4% over one year, with a market value of about ₩916.5B. Revenue has grown over five years, but operating margin has dropped from 14.8% in 2023 to 4.3% on a trailing basis.

Written Oct 18, 2026 · Data as of Oct 16, 2026 · 0 views

This is not financial advice. The report does not recommend buying or selling anything.

XfWATGr/in@

Thesis

The data supports a picture of a company with growing sales but weaker profitability. Revenue rose from ₩1.34T in 2021 to ₩1.78T on a trailing basis, yet operating income fell from ₩246.6B in 2023 to ₩77.2B. The shares now trade at 0.9 times book value and 11.5 times earnings, below their own year-end levels in 2024 and 2025. That reflects lower returns, with ROE at 8.3% versus 29.6% in 2023. The data does not explain why margins fell, so the cause cannot be stated here. Free cash flow is negative at -₩65.4B, which counts against the picture. Foreign ownership has edged down from 16.2% to 15.5% over 60 days, and short-interest data is not available.

Business overview

Chong Kun Dang Pharmaceutical is listed on KOSPI in the Biotech & Pharma sector, with 13.8M listed shares and a market capitalisation of about ₩916.5B. The company was founded on 2013-11-05 and listed on 2013-12-06. Annual revenue was ₩1.34T in 2021, ₩1.49T in 2022, ₩1.67T in 2023, ₩1.59T in 2024 and ₩1.69T in 2025. Among the recent headlines, a group affiliate launched an eye-health product, but the data does not show any financial effect on the company.

Every earlier JONBUR Research report and update note on Chong Kun Dang Pharmaceutical, with Pro.

Unlock with Pro

Model estimate of fair value

Bear
₩0
-100%
Base
₩36,731
-40%
Bull
₩110,507
+80%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Base case of the 5-year discounted cash flow model on the stock's Valuation tab (statements TTM to H1 2026; discount rate 7.2%). Bear and Bull move the main assumptions by fixed steps. See and change the assumptions

Filings and data used

Report history

  1. Oct 21, 2026Update noteModel fair value changeChong Kun Dang: Model Fair Value Estimate Rises to ₩88,607 per Share from ₩36,731
  2. Oct 18, 2026InitiationStart of coverage (reader request)Chong Kun Dang Pharmaceutical: Margins Have Fallen from the 2023 Peak While Shares Trade Near Book Value

Built only from jonbur's own data: prices and investor flows, filed financial statements and filings, and news headlines. Disclosed (filed) data is labelled as such. Written by AI and may contain mistakes.

This is not financial advice. The report does not recommend buying or selling anything.

Source: KRX statistical information